Equities

Deva Holding AS

DEVA.E:IST

Deva Holding AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TRY)75.35
  • Today's Change2.00 / 2.73%
  • Shares traded1.12m
  • 1 Year change+93.21%
  • Beta0.8661
Data delayed at least 15 minutes, as of Apr 30 2024 16:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Deva Holding AS is a Turkey-based pharmaceutical company that is primarily engaged in the production and marketing of finished pharmaceutical products, pharmaceutical ingredients and veterinary products, as well as animal health products, among others. The Company has four production facilities in Turkey. Its production facilities include the Tokapi, Cerezkoy I, Cerezkoy II and Kartepe production plants. The Company’s product portfolio comprises 73 drugs, which are available on the market in 177 various forms. It offers products, such as Azitro, Alemax, Cefax, Inhibace, Imatis, Hydrea, Kardozin, Kristapen, Magcar, Magnesie Calcinee, Nostil, Oceral, Remidon, Prolixin and Quet, among others. The Company has two subsidiaries, namely Vetaa Veteriner ve Tarim Ilaclari A.S. and Deva Holding NZ Ltd.

  • Revenue in TRY (TTM)7.64bn
  • Net income in TRY2.31bn
  • Incorporated1958
  • Employees2.93k
  • Location
    Deva Holding ASKucukcekmeceISTANBUL 34303TurkeyTUR
  • Phone+90 2 126929292
  • Fax+90 2 126970208
  • Websitehttps://www.deva.com.tr
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Oxford BioMedica plc3.65bn-6.43bn10.61bn891.00--3.40--2.90-1.63-1.630.92730.76450.25133.912.57---51.69-19.60-64.26-24.6844.3750.74-205.68-44.382.90-11.290.5888---36.046.04-302.20---0.6307--
Hyloris Pharmaceuticals SA98.02m-549.03m11.41bn24.00--8.44--116.42-0.5795-0.57950.10351.390.0514--0.61---28.80-22.79-32.58-28.0796.7093.79-560.13-640.15----0.0432--44.2398.64-33.92--87.74--
Niox Group PLC1.50bn387.77m12.08bn85.0033.113.2821.298.040.02110.02380.08190.21360.38742.316.13432,941.2010.00-2.4110.57-2.9072.0170.8725.82-11.463.99--0.013--17.57-5.29-32.62---5.59--
Idorsia Ltd6.59bn-13.35bn12.57bn1.36k------1.91-2.11-2.111.04-4.650.22010.237462.89135,698.00-44.59-43.40-62.30-48.0694.92---202.54-966.501.02-26.393.77--174.70-9.29-30.46--28.72--
Nykode Therapeutics ASA418.77m-1.14bn12.71bn173.00--2.29--30.35-1.35-1.350.48615.760.0601--10.14818,784.80-16.365.65-19.006.38-----272.4818.13----0.0324--79.99282.1717.75--187.37--
Carbios SA835.99k-948.29m13.44bn134.00--1.65--16,073.54-2.03-2.030.001713.920.0001--0.7619179.10-11.20-9.92-12.13-10.77-4,783.33---113,433.30-3,365.229.43-23.970.1517---65.71-53.321.86--141.01--
Medincell SA377.83m-920.32m13.97bn138.00------36.99-1.02-1.020.4086-0.89650.2605--6.8175,853.15-63.46-59.54-115.15-117.3660.4368.38-243.58-451.26---4.291.69--141.788.96-29.04---2.87--
Deva Holding AS7.64bn2.31bn14.67bn2.93k6.362.535.861.9211.5411.5438.2028.970.74641.496.522,686,365.0022.5521.3343.2733.3756.7853.7230.2132.510.9899--0.47762.7792.1541.1116.2571.1858.49--
Guerbet SA27.37bn831.32m16.29bn2.92k20.571.235.610.59531.801.8062.1529.970.79970.59835.80269,071.902.261.402.961.8678.0176.022.821.821.215.620.503557.824.30-0.0993158.05-12.615.23-10.07
Valneva SE5.35bn-3.53bn16.81bn684.00--3.75--3.14-0.7343-0.73431.110.9240.28432.544.69224,726.60-18.76-15.39-31.44-25.0634.3735.94-65.99-34.951.37-3.570.6195---57.466.3429.21--35.18--
Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS8.15bn454.58m16.86bn622.0037.093.4923.472.071.521.5227.1716.121.166.537.7213,105,500.006.4512.398.9117.5322.0719.065.556.950.9854--0.2095---23.3847.18-28.97147.97----
Pharmanutra SpA3.49bn446.97m18.21bn105.0040.469.5434.735.221.331.3310.415.660.94260.36484.90954,304.8012.0718.3916.1224.8097.5696.3612.8117.771.8357.610.339952.5121.1316.51-14.738.4475.7111.20
Philogen SpA805.68m-214.60m18.44bn160.00--8.05--22.88-0.1551-0.15510.57472.250.18876.657.95144,562.50-5.03-7.32-5.56-8.3640.0432.04-26.64-58.666.84--0.1414---2.4610.80-14.60--51.78--
Basilea Pharmaceutica AG Allschwil5.63bn372.93m18.79bn147.0045.87--43.703.340.87650.876513.15-0.83350.79991.065.161,072,340.005.30-1.867.69-2.9983.0083.456.63-2.992.642.021.10--6.683.53-13.96--11.17--
Data as of Apr 30 2024. Currency figures normalised to Deva Holding AS's reporting currency: Turkish Lira TRY

Institutional shareholders

0.26%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 04 Apr 2024420.36k0.21%
Dimensional Fund Advisors Ltd.as of 29 Feb 202431.71k0.02%
DBX Advisors LLCas of 05 Apr 202419.58k0.01%
AK Asset Management ASas of 30 Jun 202215.00k0.01%
Legal & General Investment Management Ltd.as of 29 Feb 202412.25k0.01%
Handelsbanken Fonder ABas of 31 Mar 20249.86k0.01%
Amundi Asset Management SA (Investment Management)as of 03 Apr 20243.87k0.00%
DFA Australia Ltd.as of 31 Dec 20231.62k0.00%
Goldman Sachs Asset Management LPas of 05 Apr 20241.17k0.00%
More ▼
Data from 30 Jun 2022 - 25 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.